8-K ·Filed Mar 4, 2026
8-K context-dependent: Items 8.01
Actionable Insight • Neutral
Monitor for any future leadership transition risks or changes in executive capacity, though current messaging emphasizes stability and continuity.
Final — all horizons settled through T+60d
INDB ▼ -0.09% at T+60d
NEUTRAL call -0.09% · α vs SPY -11.39% · entry $77.62 → $77.55
T+1d
-1.39%
call -1.39% · α -0.08%
$76.54
settled 8mo ago
T+5d
-4.11%
call -4.11% · α -1.87%
$74.43
settled 8mo ago
T+20d
-1.08%
call -1.08% · α +2.71%
$76.78
settled 7mo ago
T+60d
-0.09%
call -0.09% · α -11.39%
$77.55
settled 5mo ago
Price Chart
Loading chart...
Executive Summary
Independent Bank Corp CEO Jeffrey Tengel disclosed a recent lymphoma diagnosis, stating it is highly treatable and that he plans to continue working while undergoing chemotherapy. The company confirmed no change to leadership or strategy.
Key Facts
- CEO Jeffrey Tengel diagnosed with lymphoma, described as highly treatable
- Tengel plans to continue working with adjusted schedule during treatment
- No leadership change or strategic shift announced
- Board and executive team confirmed support and continuity
- Public disclosure made via internal employee letter (Exhibit 99.1)
Financial Impact
No immediate financial impact disclosed
Risk Factors
- Potential leadership disruption if treatment impacts CEO availability
- Market perception risk around executive health and succession planning
Market Snapshot
Exchange
Nasdaq
Investment Themes
Traditional Finance
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000776901-26-000061 |
| Exhibit: exhibit991-letterofjefften.htm | 0000776901-26-000061 |
| Document: 0000776901-26-000061-index-headers.html | 0000776901-26-000061 |
| Document: 0000776901-26-000061-index.html | 0000776901-26-000061 |
| Document: 0000776901-26-000061.txt | 0000776901-26-000061 |
8 reports for INDB
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | S-3ASR | $83.72 | awaiting T+5 | — | $83.70 (−0.02%) |
Oct 15, 2026 11d ago | 8-K | $79.88 $83.72 | ▼ −4.81% | ▼ −5.24% | $83.70 (−4.78%) |
Jul 27, 2026 13w ago | 8-K | $86.14 $85.00 | ▼ −1.32% | ▼ −3.59% | $83.70 (−2.83%) |
Jun 18, 2026 18w ago | 8-K | $81.40 $85.19 | ▲ +4.66% | ▲ +6.72% | $83.70 (+2.83%) |
Apr 16, 2026 27w ago | 8-K | $77.95 $77.75 | ▼ −0.26% | ▼ −0.81% | $83.70 (+7.38%) |
Apr 13, 2026 28w ago | 8-K | $80.04 $77.67 | ▼ −2.96% | ▼ −4.36% | $83.70 (+4.57%) |
Apr 1, 2026 29w ago | DEFA14A | $76.78 $79.62 | ▲ +3.70% | ▲ +0.08% | $83.70 (+9.01%) |
Mar 4, 2026 33w ago | 8-K | $77.62 $74.43 | ▼ −4.11% | ▼ −1.87% | $83.70 (+7.83%) |
Showing 8 of 8
US Market Status
Market Closed — Opens in 8h 13m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers